Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis via Triggered GPX4 Inhibition and Concurrent In Situ Bleomycin Toxification

Given that traditional Anticancer therapies fail to significantly improve the prognoses of triple negative breast Cancer (TNBC), new modalities with high efficiency are urgently needed. Herein, by mixing the metal-phenolic network formed by tannic acid (TA), bleomycin (BLM), and Fe³⁺ with Glutathione Peroxidase 4 (GPX4) inhibitor (ML210) loaded hollow mesoporous Prussian blue (HMPB) nanocubes, the HMPB/ML210@TA-BLM-Fe³⁺ (HMTBF) nanocomplex is prepared to favor the Ferroptosis/Apoptosis synergism in TNBC. During the intracellular degradation, Fe³⁺ /Fe²⁺ conversion mediated by TA can initiate the Fenton reaction to drastically upregulate the Reactive Oxygen Species level in cells, subsequently induce the accumulation of lipid peroxidation, and thereby cause ferroptotic cell death; meanwhile, the released ML210 efficiently represses the activity of GPX4 to activate Ferroptosis pathway. Besides, the chelation of Fe²⁺ with BLM leads to in situ BLM toxification at tumor site, then triggers an effective Apoptosis to synergize with Ferroptosis for tumor therapy. As a result, the superior in vivo antitumor efficacy of HMTBF is corroborated in a 4T1 tumor-bearing mice model regarding tumor growth suppression, indicating that the nanoformulations can serve as efficient Ferroptosis and Apoptosis inducers for use in combinatorial TNBC therapy.